+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.

Age: 6Months - 11YearsAll GendersPhase 2
31 locations